Altimmune, Inc.

Altimmune is a clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual receptor agonist aimed at obesity, MASH (metabolic dysfunction–associated steatohepatitis), and — as of a fresh trial win — alcohol use disorder. The equity is a pre-revenue option on trial data, not a business.

• Revenue is functionally zero and the burn is real: recent quarterly revenue was $0 to $26K against operating expenses that produce -$0.12 to -$0.27 quarterly EPS — the stock trades on pipeline milestones and cash runway, and consensus doesn't model meaningful revenue until 2027-2028.
• The pipeline just added a credit line: RECLAIM Phase 2 in alcohol use disorder (July 28) hit its primary endpoint on heavy drinking days, which is a genuine new indication for the same molecule — the AUD market is much smaller than obesity but the Phase 2 win supports the underlying mechanism story.
• The next big number is far away: the Phase 3 MASH readout doesn't come until 2029, and that is the actual value-driver for the equity — everything between now and then is cash-runway management, interim data on secondary indications, and dilution risk when the tank gets low.
• The insider signal is small but the right direction: CEO Jerome Durso's $44K open-market buy on Aug 13 is the only real cash-out-of-pocket transaction, and it's the kind of modest-but-real conviction move a clinical-stage CEO can make ahead of a data cycle.

The path if it works is a clean interim MASH datapoint or a partnering event on pemvidutide's obesity potential ahead of the Phase 3 readout — the tape rerates on optionality, not on cash flow. The path if it doesn't is a routine dilution round or a Phase 3 delay that pushes the 2029 readout deeper; that's when a stock at 14% of its 52-week range extends its drift lower rather than coiling into a bounce.